If
the Canadian pharmaceuticals market was a high school, Domenic Pilla and Frank Scorpiniti would be the heads of rival cliques.
Not exact matches
Back when the
Canadian dollar was trading roughly at par with the U.S. dollar (and briefly above it), it was a great opportunity for
Canadian investors to diversify outside of the
Canadian equity
market to buy world - class U.S. stocks in sectors underrepresented in Canada: technology, health care,
pharmaceuticals, consumer staples and the like.
That seemed rather unusual to me since the US /
Canadian veterinary
pharmaceutical market is the most lucrative in the world.
Currently, Canada is the only country that allows brand name
pharmaceutical companies to sue generic
pharmaceutical companies multiple times on the same patents, adding to the costs and risks of bringing generic drug competition to the
Canadian market.
The article contains an overview of some of the most pertinent changes in
market access, exclusivity and pricing that have occurred over the past year that will impact stakeholders operating in the
Canadian pharmaceutical industry.